We are live on ! Find out more
BIO icon

Bio-Rad Laboratories Class A

271 hedge funds and large institutions have $4.27B invested in Bio-Rad Laboratories Class A in 2017 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 81 increasing their positions, 119 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

117% more call options, than puts

Call options by funds: $2.8M | Put options by funds: $1.29M

1.45% more ownership

Funds ownership: 76.8%78.25% (+1.4%)

0% more capital invested

Capital invested by funds: $4.26B → $4.27B (+$9.01M)

9% less first-time investments, than exits

New positions opened: 30 | Existing positions closed: 33

2% less funds holding

Funds holding: 276271 (-5)

32% less repeat investments, than reductions

Existing positions increased: 81 | Existing positions reduced: 119

40% less funds holding in top 10

Funds holding in top 10: 106 (-4)

Holders
271
Holders Change
-5
Holders Change %
-1.81%
% of All Funds
6.76%
Holding in Top 10
6
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-40%
% of All Funds
0.15%
New
30
Increased
81
Reduced
119
Closed
33
Calls
$2.8M
Puts
$1.29M
Net Calls
+$1.51M
Net Calls Change
+$1.44M
Name Holding Trade Value Shares
Change
Change in
Stake
FMW
201
Farr Miller & Washington
District of Columbia
$384K +$4.73K +21 +1%
IG
202
ING Group
Netherlands
$383K -$182K -809 -32%
OI
203
Oakbrook Investments
Illinois
$383K +$11.3K +50 +3%
MCIM
204
Meadow Creek Investment Management
Georgia
$376K +$44.6K +198 +13%
HighTower Advisors
205
HighTower Advisors
Illinois
$375K -$1.35K -6 -0.4%
LIA
206
LS Investment Advisors
Michigan
$368K -$14.4K -64 -4%
Creative Planning
207
Creative Planning
Kansas
$346K +$39.8K +177 +13%
SCM
208
Shelton Capital Management
Colorado
$344K
NI
209
Numeric Investors
Massachusetts
$333K -$225K -1,000 -40%
HSBC Holdings
210
HSBC Holdings
United Kingdom
$319K +$56K +249 +21%
Barclays
211
Barclays
United Kingdom
$307K -$656K -2,917 -68%
LIM
212
Leavell Investment Management
Alabama
$289K
Capstone Investment Advisors
213
Capstone Investment Advisors
New York
$288K +$293K +1,300 New
FCM
214
Flinton Capital Management
Pennsylvania
$274K +$32.4K +144 +13%
PAM
215
Panagora Asset Management
Massachusetts
$271K +$6.08K +27 +2%
Macquarie Group
216
Macquarie Group
Australia
$255K +$259K +1,150 New
NIT
217
NumerixS Investment Technologies
British Columbia, Canada
$244K +$135K +600 +120%
NBC
218
Neuberger Berman Canada
Ontario, Canada
$232K -$40.7K -181 -15%
CIBC Asset Management
219
CIBC Asset Management
Ontario, Canada
$232K -$1.8K -8 -0.8%
WAM
220
World Asset Management
Michigan
$227K -$675 -3 -0.3%
DY
221
Dowling & Yahnke
California
$224K
QI
222
QS Investors
New York
$224K
LTFS
223
Ladenburg Thalmann Financial Services
Florida
$223K -$27.2K -121 -11%
TSW
224
Thompson Siegel & Walmsley
Virginia
$222K -$422K -1,875 -65%
SF
225
Synovus Financial
Georgia
$222K +$15.1K +67 +7%

BIO Hedge Fund Activity: Q3 2017 in Review

271 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q3 2017, worth a combined $4.27B — up 0.21% from $4.26B a quarter earlier.

Sellers outnumbered buyers: 33 funds closed out of BIO and 30 opened new positions — a net loss of 3 holders — while 119 trimmed existing stakes and 81 added.

The largest buyer was American Century Companies, opening a new position worth an estimated $127M. The largest seller was Fidelity Investments, cutting an estimated $124M.

  • 271 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q3 2017, down from 276 in Q2 2017.
  • Funds reported $4.27B of Bio-Rad Laboratories Class A stock for Q3 2017, up 0.21% quarter-over-quarter.
  • 30 funds opened new Bio-Rad Laboratories Class A positions in Q3 2017 and 33 closed out, a net change of -3 holders.
  • The largest Bio-Rad Laboratories Class A buyer in Q3 2017 was American Century Companies, an estimated $127M added.
  • The largest Bio-Rad Laboratories Class A seller in Q3 2017 was Fidelity Investments, an estimated $124M sold.

Based on aggregated 13F filings for Q3 2017.